A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib-Reference-Cited by-同舟云学术

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib

Published:2017-06 Issue: Volume:108 Page:154-160
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Moran Teresa,Palmero Ramón,Provencio Mariano,Insa Amelia,Majem Margarita,Reguart Noemí,Bosch-Barrera Joaquim,Isla Dolores,Costa Enric Carcereny,Lee Chooi,Puig Marta,Kraemer Sandrine,Schnell David,Rosell Rafael

Funder

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Personalized cancer therapy gets closer;Hayden;Nature,2009

2. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer;Sequist;J. Clin. Oncol.,2007

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med.,2004

4. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

5. Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small-cell lung cancer (aNSCLC) treated with gefitinib or placebo (ISEL trial);Hirsch;Clin. Cancer Res.,2005

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MLIP and Its Potential Influence on Key Oncogenic Pathways;Cells;2024-06-26

2. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities;Pharmacological Research;2024-04

3. Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFR^T790M/L858R inhibitors for the treatment of non‐small cell lung cancer;Archiv der Pharmazie;2024-02-21

4. State-of-the-art review of theabrownins: from preparation, structural characterization to health-promoting benefits;Critical Reviews in Food Science and Nutrition;2023-08-16

5. Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects;Frontiers in Immunology;2023-08-15